MannKind Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes.

Our lead product, Afrezza is a rapid-acting inhaled insulin indicated to improve glycemic control in adults patients with type 1 and type 2 diabetes. The product was approved by the FDA in 2014 and consists of Afrezza Inhalation Powder single-use dose cartridges, and the small, discreet, and easy-to-use Afrezza Inhaler.